Chimeric antigen receptor–natural killer (CAR-NK) cells are drawing renewed attention as an immunotherapy platform that pairs innate tumor-killing ability with antigen-directed precision, and a new comprehensive review in the Journal of Cancer Research and Clinical Oncology sets out where the field stands. The review, published as an open-access article, synthesizes recent preclinical and early-phase clinical studies covering CAR design, transduction technologies, gene editing, manufacturing and expansion protocols, and trial outcomes in both hematological malignancies and solid tumors.
According to the review's authors, CAR-NK cells promise lower cytokine toxicity than CAR-T approaches. The cells can kill through multiple routes, combining CAR-dependent recognition with innate cytotoxic pathways, and they hold potential for allogeneic, “off-the-shelf” use, meaning donor-derived products that would not require manufacturing from each patient’s own cells. Early safety profiles reported in the literature the review examined were described as favorable.
Yet the review is equally clear that clinical translation remains constrained. NK-specific obstacles persist, including lower viral transduction efficiencies than those achieved in T cells, short in vivo persistence after infusion, poor infiltration into solid tumors, and suppression by the tumor microenvironment. The review catalogs the microenvironmental factors implicated, including TGF-β signaling, adenosine, and metabolic stress within the tumor milieu.
A substantial portion of the review is devoted to engineering countermeasures designed to address these weaknesses. Interleukin-15 expression has been used to support NK cell survival and persistence, while knockout of checkpoint receptors aims to reduce inhibitory signaling in the immunosuppressive tumor setting. Co-expression of chemokine receptors such as CXCR1 and CXCR4 is presented as a strategy to improve trafficking and infiltration into solid tumors, where physical and chemical barriers currently limit delivery of the therapeutic cells.
Signaling domain design also features prominently. The review discusses DAP10- and DAP12-based signaling domains as engineering choices that shape how CAR-NK cells activate upon encountering their target antigen.
On the manufacturing side, non-viral delivery methods, including transposon systems and CRISPR-based editing, are described as having shown preclinical promise. These approaches could address the transduction efficiency bottleneck that has limited viral vector-based engineering of NK cells, although the review frames these results as preclinical rather than established clinical practice.
The review’s overall assessment is that CAR-NK therapy has developed from concept to a clinically actionable treatment line for hematological malignancies, with emerging potential in solid tumors when combined with strategies that modulate the tumor microenvironment. That distinction matters: progress in blood cancers has not yet been matched in solid tumors, where infiltration and microenvironment suppression remain the central hurdles identified in the literature the authors surveyed.
As a review article, the work aggregates and interprets existing studies rather than presenting new experimental data, and its conclusions rest on preclinical work and early-phase clinical studies. The authors state that the review emphasizes the challenges CAR-NK therapies encounter, the strategies and innovative approaches proposed to overcome them, and forward-looking perspectives intended to improve future therapeutic CAR-NK designs and clinical outcomes. For readers tracking cell therapy development, the review positions CAR-NK cells as a platform whose safety advantages are increasingly documented, while its clinical reach still depends on solving persistence, trafficking, and microenvironment resistance through continued engineering.
Subject of Research: Engineering strategies and clinical applications of CAR-NK cell immunotherapy in hematological and solid tumors
Article Title: CAR-NK cell immunotherapy: a comprehensive review of engineering platforms, clinical applications in hematological and solid tumors
Article References: Awadallah, S. M., Elmesalamy, N., Bahr, A. R., Atef, B., Afroz, E., & Hill, H. C. (2026). CAR-NK cell immunotherapy: a comprehensive review of engineering platforms, clinical applications in hematological and solid tumors. Journal of Cancer Research and Clinical Oncology, 152(10), Article 202. https://doi.org/10.1007/s00432-026-06635-1
Image Credits: AI Generated
DOI: 10.1007/s00432-026-06635-1
Keywords: CAR-NK cells, immunotherapy, natural killer cells, hematological malignancies, solid tumors, tumor microenvironment, IL-15, gene editing, CRISPR, allogeneic cell therapy, checkpoint receptors, cell engineering
News Source: Denise Maddox. (October 29, 2026). CAR-NK Cells Move From Concept Toward Clinic as Review Maps Engineering Fixes. Scienmag.
